>

Cancer cell (HeLa line)

Q: Can I use the Cancer cell (HeLa line) icon in a BioRender figure or scientific illustration?

Yes — the Cancer cell (HeLa line) is fully integrated into BioRender's drag-and-drop platform. You can easily add it to any scientific figure, workflow, or poster, whether you're building from scratch or starting with a BioRender template.

Q: Can I export figures that include the Cancer cell (HeLa line) icon for publication or presentations?

Yes — figures containing the Cancer cell (HeLa line) icon can be exported in multiple formats, including PNG, JPG, PDF, and SVG. High-resolution and vector exports are available on paid plans, making them ideal for journals, slide decks, and print materials.

Cancer cell (HeLa line) - Editable icon of A triangular HeLa cancer cell with thin projections.

[{"image":"https://icons.cdn.biorender.com/w75xh75/60ba4247d6c9560027a6f64e/60ba4188d6c9560027a6f61c.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/60ba4247d6c9560027a6f64e/60ba4188d6c9560027a6f61c.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/60ba4247d6c9560027a6f64d/60ba4188d6c9560027a6f61c.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/60ba4247d6c9560027a6f64d/60ba4188d6c9560027a6f61c.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/60ba4247d6c9560027a6f64c/60ba4188d6c9560027a6f61c.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/60ba4247d6c9560027a6f64c/60ba4188d6c9560027a6f61c.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/60ba4247d6c9560027a6f64b/60ba4188d6c9560027a6f61c.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/60ba4247d6c9560027a6f64b/60ba4188d6c9560027a6f61c.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/60ba4247d6c9560027a6f64a/60ba4188d6c9560027a6f61c.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/60ba4247d6c9560027a6f64a/60ba4188d6c9560027a6f61c.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/60ba4247d6c9560027a6f649/60ba4188d6c9560027a6f61c.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/60ba4247d6c9560027a6f649/60ba4188d6c9560027a6f61c.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/60ba4247d6c9560027a6f648/60ba4188d6c9560027a6f61c.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/60ba4247d6c9560027a6f648/60ba4188d6c9560027a6f61c.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/60ba4247d6c9560027a6f647/60ba4188d6c9560027a6f61c.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/60ba4247d6c9560027a6f647/60ba4188d6c9560027a6f61c.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/60ba4247d6c9560027a6f646/60ba4188d6c9560027a6f61c.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/60ba4247d6c9560027a6f646/60ba4188d6c9560027a6f61c.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/60ba4247d6c9560027a6f645/60ba4188d6c9560027a6f61c.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/60ba4247d6c9560027a6f645/60ba4188d6c9560027a6f61c.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/60ba4247d6c9560027a6f644/60ba4188d6c9560027a6f61c.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/60ba4247d6c9560027a6f644/60ba4188d6c9560027a6f61c.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/60ba4247d6c9560027a6f643/60ba4188d6c9560027a6f61c.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/60ba4247d6c9560027a6f643/60ba4188d6c9560027a6f61c.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/60ba4247d6c9560027a6f642/60ba4188d6c9560027a6f61c.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/60ba4247d6c9560027a6f642/60ba4188d6c9560027a6f61c.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/60ba4247d6c9560027a6f641/60ba4188d6c9560027a6f61c.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/60ba4247d6c9560027a6f641/60ba4188d6c9560027a6f61c.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/60ba4247d6c9560027a6f640/60ba4188d6c9560027a6f61c.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/60ba4247d6c9560027a6f640/60ba4188d6c9560027a6f61c.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/60ba4247d6c9560027a6f63f/60ba4188d6c9560027a6f61c.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/60ba4247d6c9560027a6f63f/60ba4188d6c9560027a6f61c.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/60ba4247d6c9560027a6f63e/60ba4188d6c9560027a6f61c.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/60ba4247d6c9560027a6f63e/60ba4188d6c9560027a6f61c.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/60ba4247d6c9560027a6f63d/60ba4188d6c9560027a6f61c.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/60ba4247d6c9560027a6f63d/60ba4188d6c9560027a6f61c.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/60ba4247d6c9560027a6f63c/60ba4188d6c9560027a6f61c.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/60ba4247d6c9560027a6f63c/60ba4188d6c9560027a6f61c.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/60ba4247d6c9560027a6f63b/60ba4188d6c9560027a6f61c.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/60ba4247d6c9560027a6f63b/60ba4188d6c9560027a6f61c.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/60ba4247d6c9560027a6f63a/60ba4188d6c9560027a6f61c.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/60ba4247d6c9560027a6f63a/60ba4188d6c9560027a6f61c.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/60ba4247d6c9560027a6f639/60ba4188d6c9560027a6f61c.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/60ba4247d6c9560027a6f639/60ba4188d6c9560027a6f61c.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/60ba4247d6c9560027a6f638/60ba4188d6c9560027a6f61c.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/60ba4247d6c9560027a6f638/60ba4188d6c9560027a6f61c.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/60ba4247d6c9560027a6f637/60ba4188d6c9560027a6f61c.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/60ba4247d6c9560027a6f637/60ba4188d6c9560027a6f61c.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/60ba4247d6c9560027a6f636/60ba4188d6c9560027a6f61c.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/60ba4247d6c9560027a6f636/60ba4188d6c9560027a6f61c.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/60ba4247d6c9560027a6f635/60ba4188d6c9560027a6f61c.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/60ba4247d6c9560027a6f635/60ba4188d6c9560027a6f61c.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/60ba4247d6c9560027a6f634/60ba4188d6c9560027a6f61c.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/60ba4247d6c9560027a6f634/60ba4188d6c9560027a6f61c.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/60ba4247d6c9560027a6f633/60ba4188d6c9560027a6f61c.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/60ba4247d6c9560027a6f633/60ba4188d6c9560027a6f61c.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/60ba4247d6c9560027a6f632/60ba4188d6c9560027a6f61c.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/60ba4247d6c9560027a6f632/60ba4188d6c9560027a6f61c.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/60ba4247d6c9560027a6f631/60ba4188d6c9560027a6f61c.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/60ba4247d6c9560027a6f631/60ba4188d6c9560027a6f61c.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/60ba4247d6c9560027a6f630/60ba4188d6c9560027a6f61c.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/60ba4247d6c9560027a6f630/60ba4188d6c9560027a6f61c.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/60ba4247d6c9560027a6f62f/60ba4188d6c9560027a6f61c.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/60ba4247d6c9560027a6f62f/60ba4188d6c9560027a6f61c.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/60ba4247d6c9560027a6f62e/60ba4188d6c9560027a6f61c.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/60ba4247d6c9560027a6f62e/60ba4188d6c9560027a6f61c.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/60ba4247d6c9560027a6f62d/60ba4188d6c9560027a6f61c.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/60ba4247d6c9560027a6f62d/60ba4188d6c9560027a6f61c.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/60ba4247d6c9560027a6f62c/60ba4188d6c9560027a6f61c.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/60ba4247d6c9560027a6f62c/60ba4188d6c9560027a6f61c.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/60ba4247d6c9560027a6f62b/60ba4188d6c9560027a6f61c.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/60ba4247d6c9560027a6f62b/60ba4188d6c9560027a6f61c.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/60ba4247d6c9560027a6f62a/60ba4188d6c9560027a6f61c.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/60ba4247d6c9560027a6f62a/60ba4188d6c9560027a6f61c.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/60ba4247d6c9560027a6f629/60ba4188d6c9560027a6f61c.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/60ba4247d6c9560027a6f629/60ba4188d6c9560027a6f61c.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/60ba4247d6c9560027a6f628/60ba4188d6c9560027a6f61c.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/60ba4247d6c9560027a6f628/60ba4188d6c9560027a6f61c.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/60ba4247d6c9560027a6f627/60ba4188d6c9560027a6f61c.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/60ba4247d6c9560027a6f627/60ba4188d6c9560027a6f61c.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/60ba4247d6c9560027a6f626/60ba4188d6c9560027a6f61c.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/60ba4247d6c9560027a6f626/60ba4188d6c9560027a6f61c.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/60ba4247d6c9560027a6f625/60ba4188d6c9560027a6f61c.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/60ba4247d6c9560027a6f625/60ba4188d6c9560027a6f61c.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/60ba4247d6c9560027a6f624/60ba4188d6c9560027a6f61c.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/60ba4247d6c9560027a6f624/60ba4188d6c9560027a6f61c.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/60ba4247d6c9560027a6f623/60ba4188d6c9560027a6f61c.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/60ba4247d6c9560027a6f623/60ba4188d6c9560027a6f61c.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/60ba4247d6c9560027a6f622/60ba4188d6c9560027a6f61c.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/60ba4247d6c9560027a6f622/60ba4188d6c9560027a6f61c.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/60ba4247d6c9560027a6f621/60ba4188d6c9560027a6f61c.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/60ba4247d6c9560027a6f621/60ba4188d6c9560027a6f61c.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/60ba4247d6c9560027a6f620/60ba4188d6c9560027a6f61c.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/60ba4247d6c9560027a6f620/60ba4188d6c9560027a6f61c.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/60ba4247d6c9560027a6f61f/60ba4188d6c9560027a6f61c.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/60ba4247d6c9560027a6f61f/60ba4188d6c9560027a6f61c.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/60ba4247d6c9560027a6f61e/60ba4188d6c9560027a6f61c.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/60ba4247d6c9560027a6f61e/60ba4188d6c9560027a6f61c.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/60ba4247d6c9560027a6f61d/60ba4188d6c9560027a6f61c.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/60ba4247d6c9560027a6f61d/60ba4188d6c9560027a6f61c.png"}]

Keywords

keyword text

HeLa,HeLa cell,cancer cell,immortal,cell line,cell clone,durable,prolific,cancer research,cancer study,virus research,genetics,Henrietta Lacks,Lacks,cervical cancer cells,hela

BioRender icons and templates meet journal, grant, and copyright standards. For AI-generated figures, policies vary. Learn More

More Icons like this one in

Related Categories

Back To Library Home

Join 1,500,000 other scientists on BioRender

Sign up for your free account and start creating scientific figures faster today

Sign Up Free

FAQs

What is BioRender?

BioRender is a web‑based software that helps you create scientific figures in minutes. Use this Cancer cell (HeLa line) icon along with our library of more than 30,000 life science icons.

Can I use this icon in a BioRender figure or scientific illustration?

Yes, the Cancer cell (HeLa line) is fully integrated into BioRender’s drag-and-drop platform. You can easily add it to any scientific figure, workflow, or poster, whether you’re building from scratch or starting with a BioRender template.

Is the Cancer cell (HeLa line) icon customizable in BioRender?

Most icons in BioRender, including the Cancer cell (HeLa line) icon, are customizable. You can adjust icon size, colors, and positioning, and add custom labels to tailor the design to your specific research context.

How are scientists using the Cancer cell (HeLa line) icon in their work?

BioRender users often use the Cancer cell (HeLa line) icon in posters, grant applications, educational materials, and graphical abstracts. It’s especially useful for projects involving Cell Types.

Can I export figures that include the Cancer cell (HeLa line) icon for publication or presentations?

Yes, figures containing the Cancer cell (HeLa line) icon can be exported in multiple formats, including PNG, JPG, PDF, and SVG. High-resolution and vector exports are available on paid plans, making them ideal for journals, slide decks, and print materials.

Is the Cancer cell (HeLa line) icon used in BioRender templates or poster layouts?

Many BioRender templates include icons like the Cancer cell (HeLa line) icon — especially those focused on Cell Types. You can search BioRender’s template library or add this icon manually to any canvas.

Make scientific figures in minutes

Cancer cell (HeLa line)

Join 1,500,000 other scientists on BioRender

FAQs

Looking for science content?